logo
Share SHARE
FONT-SIZE Plus   Neg

Corcept Therapeutics Q4 Loss Widens

Corcept Therapeutics Inc. (CORT: Quote) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.

Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.

During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM) Tuesday said its U.S. sales for February rose 13.3 percent, as the Japanese automaker attracted new customers helped by strong marketing and plunging oil prices. Toyota's U.S. sales in February increased 13.3 percent to 180,467 units from 159,284 units a year ago. Sales... United Airlines has announced it will not accept bulk shipments of rechargeable lithium batteries, citing safety concerns. United Airlines becomes the second major airline in the U.S. to stop accepting bulk shipment of lithium batteries, after Delta Air Lines made a similar announcement last month. Tests... An online documentary by a Chinese journalist providing insight into the alarming level of smog in her country has attracted millions of views and led to wide-ranging debates among netizens.
comments powered by Disqus
Follow RTT